Months after acquiring Cambridge-based ReNAgade Therapeutics, Watertown’s Orna Therapeutics is laying off workers. Orna, a ...

Compared to DNA sequencing alone, concurrent DNA and RNA sequencing revealed more clinically actionable variants in NSCLC.

The firm has made significant strides in its RNA editing and RNA interference programs, which are attracting positive attention and positioning the company for differentiation in the treatment of ...

Orna was part of a buzzy cohort of companies established in the wake of the Covid pandemic, planning to create new, more ...

Nearly three decades later, drug makers have developed six approved small interfering RNA (siRNA) therapeutics in the ...

An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...

On October 16, a biotechnology company in Massachusetts in the U.S. named Wave Life Sciences made headlines for becoming the ...

TD Cowen analyst Ritu Baral maintained a Buy rating on Avidity Biosciences (RNA – Research Report) today and set a price target of $78.00. The company’s shares closed yesterday at $46.73. Baral covers ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

Genes contain instructions for making proteins, and a central dogma of biology is that this information flows from DNA to RNA ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...